Securing £90m Series A Financing to Advance NMTi-ADC Therapeutics
Monday, 8 July 2024, 03:12
Myricx Bio Secures £90m Series A Financing
Myricx Bio has announced the successful acquisition of £90m in Series A financing to drive forward its NMTi-ADC therapeutics.
Advancing Novel Treatments to Clinical Development
This substantial financial boost enables Myricx Bio to expedite the development of innovative therapies into clinical phases, unlocking new possibilities in biopharmaceutical research.
- Accelerating Research Efforts: The funding paves the way for Myricx Bio to intensify its research endeavors and explore the full potential of its drug candidates.
- Bringing Transformative Therapies: With this investment, Myricx Bio is one step closer to introducing groundbreaking treatments to address unmet medical needs.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.